Study drug combination for metastatic colon cancer with prior treatments
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests a chemotherapy combination (liposomal irinotecan), along with TAS-102 and bevacizumab, in people with metastatic colon cancer. It may help if your tumor has mismatch repair–proficient features and you’ve already tried standard colon cancer drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years of age or older
- Be able to do most daily activities (ECOG performance 0–1)
- Have confirmed metastatic or unresectable colon (colorectal) adenocarcinoma
- Your tumor must be mismatch repair proficient (not mismatch repair deficient or MSI-high)
- Have had prior colon cancer treatment including 5-fluorouracil and oxaliplatin, and irinotecan-type therapy; and meet specific prior-treatment rules for certain tumor types
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (irinotecan, TAS-102, and bevacizumab) for people with metastatic colorectal cancer that has already been treated with oxaliplatin-based chemotherapy. The goal is to see if this three-drug combination works better as a second treatment option.
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
This trial is testing a combination of three drugs (liposomal irinotecan, capecitabine, and bevacizumab) for people with metastatic colorectal cancer whose first-line treatment failed. The goal is to see if this combo works better as a second option.
This study tests a combination of several cancer drugs (irinotecan, capecitabine, bevacizumab, and camrelizumab) in people with metastatic colorectal cancer who have already tried at least one prior treatment. The goal is to see if these drugs work better together for patients who don't have certain genetic features.
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.